Oncogenic KRAS triggers MAPK-dependent errors in mitosis and MYC-dependent sensitivity to anti-mitotic agents

Area of Science:

• Cell Biology
• Molecular Oncology
• Cancer Therapeutics

Background:

• Oncogenic KRAS drives cancer but its role in cell division is unclear.
• Cancer cells with KRAS mutations show sensitivity to anti-mitotic drugs, but mechanisms are unknown.
• Understanding KRAS effects on mitosis is crucial for targeted cancer therapies.

Purpose of the Study:

• Investigate how oncogenic KRAS impacts cell division and mitosis.
• Determine the mechanisms linking KRAS, mitosis, and anti-mitotic drug sensitivity.
• Identify patient subgroups that may benefit from anti-mitotic therapies.

Main Methods:

• Acute expression of oncogenic KRAS in HeLa cells.
• Analysis of MAPK pathway activation and mitosis-related gene expression.
• Assessment of sensitivity to anti-mitotic agents.
• Correlation analysis with KRAS mutational status and MYC expression in drug response databases.

Main Results:

• Oncogenic KRAS expression caused mitotic delay and chromosome segregation defects via MAPK signaling.
• This led to increased sensitivity to anti-mitotic drugs, dependent on MYC and BCL-XL.
• No direct correlation found between KRAS status/MYC levels and drug sensitivity in large datasets.
• Co-existence of KRAS mutations and high MYC expression predicted sensitivity.

Conclusions:

• Oncogenic KRAS plays a novel role in regulating accurate mitotic progression.
• MYC and BCL-XL are key mediators of KRAS-induced anti-mitotic drug sensitivity.
• Combined KRAS mutation and high MYC expression can predict patient response to anti-mitotic drugs.
• Findings offer new therapeutic strategies for KRAS-mutant tumors and patient stratification.